The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at NYUH. The study is currently conducting formative data collection for tool refinement (Phase 1). Once completed, a cluster randomized controlled trial of the AIManage tool will be undertaken (Phase 2).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
16
GenAI-powered CDS tool that provides a range of IMM management services, such as personalized guidance for patients on side effects management and clinical advisement to optimize dose titrations.
NYU Langone Health
New York, New York, United States
Percentage of Patients who Complete Qualitative Measure - Perceived Usefulness
In Phase 1, qualitative data regarding perceived usefulness will be collected.
Time frame: Day 1 (60 minutes)
Percentage of Patients who Complete Qualitative Measure - Perceived Usability
In Phase 1, qualitative data regarding perceived usability will be collected.
Time frame: Day 1 (60 minutes)
Percentage of Patients who Complete Qualitative Measure - Perceived Use Challenges
In Phase 1, qualitative data regarding perceived use challenges will be collected.
Time frame: Day 1 (60 minutes)
Percentage of Patients who Complete Qualitative Measure - Perceived Value
In Phase 1, qualitative data regarding perceived value will be collected.
Time frame: Day 1 (60 minutes)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.